4.6 Article

Marijuana withdrawal and craving:: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes

期刊

ADDICTION
卷 103, 期 10, 页码 1678-1686

出版社

WILEY
DOI: 10.1111/j.1360-0443.2008.02292.x

关键词

cannabis; CNR1; craving; cues; FAAH; genes; marijuana; withdrawal

资金

  1. National Institute on Alcoholism and Alcohol Abuse [AA015331, AA012238]

向作者/读者索取更多资源

Aim To examine whether withdrawal after abstinence and cue-elicited craving were associated with polymorphisms within two genes involved in regulating the endocannabinoid system, cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH). Two single nucleotide polymorphisms (SNPs) in the CNR1 (rs2023239) and FAAH (rs324420) genes, associated previously with substance abuse and functional changes in cannabinoid regulation, were examined in a sample of daily marijuana smokers. Participants Participants were 105 students at the University of Colorado, Boulder between the ages of 18 and 25 years who reported smoking marijuana daily Measurements Participants were assessed once at baseline and again after 5 days of abstinence, during which they were exposed to a cue-elicited craving paradigm. Outcome measures were withdrawal and craving collected using self-reported questionnaires. In addition, urine samples were collected at baseline and on day 5 for the purposes of 11-nor-9-carboxy-Delta 9-tetrahydrocannabinol (THC-COOH) metabolite analysis. Findings Between the two sessions, THC-COOH metabolite levels decreased significantly, while measures of withdrawal and craving increased significantly. The CNR1 SNP displayed a significant abstinence x genotype interaction on withdrawal, as well as a main effect on overall levels of craving, while the FAAH SNP displayed a significant abstinence x genotype interaction on craving. Conclusions These genetic findings may have both etiological and treatment implications. However, longitudinal studies will be needed to clarify whether these genetic variations influence the trajectory of marijuana use/dependence. The identification of underlying genetic differences in phenotypes such as craving and withdrawal may aid genetically targeted approaches to the treatment of cannabis dependence.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms

Joseph P. Schacht, Raymond F. Anton, Patrick J. McNamara, Yeongbin Im, Andrea C. King

ADDICTION BIOLOGY (2019)

Article Substance Abuse

Brain Glutamate, GABA, and Glutamine Levels and Associations with Recent Drinking in Treatment-Naive Individuals with Alcohol Use Disorder Versus Light Drinkers

James J. Prisciandaro, Joseph P. Schacht, Andrew P. Prescot, Perry F. Renshaw, Truman R. Brown, Raymond F. Anton

ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2019)

Article Psychology, Clinical

Investigating a novel fMRI cannabis cue reactivity task in youth

Hollis C. Karoly, Joseph P. Schacht, Lindsay R. Meredith, Joanna Jacobus, Susan F. Tapert, Kevin M. Gray, Lindsay M. Squeglia

ADDICTIVE BEHAVIORS (2019)

Article Substance Abuse

Preliminary evidence that computerized approach avoidance training is not associated with changes in fMRI cannabis cue reactivity in non-treatment-seeking adolescent cannabis users

Hollis C. Karoly, Joseph P. Schacht, Joanna Jacobus, Lindsay R. Meredith, Charles T. Taylor, Susan F. Tapert, Kevin M. Gray, Lindsay M. Squeglia

DRUG AND ALCOHOL DEPENDENCE (2019)

Article Biochemistry & Molecular Biology

Intraindividual changes in brain GABA, glutamate, and glutamine during monitored abstinence from alcohol in treatment-naive individuals with alcohol use disorder

James J. Prisciandaro, Joseph P. Schacht, Andrew P. Prescot, Helena M. Brenner, Perry F. Renshaw, Truman R. Brown, Raymond F. Anton

ADDICTION BIOLOGY (2020)

Review Substance Abuse

Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder

Emily E. Hartwell, Richard Feinn, Paige E. Morris, Joel Gelernter, John Krystal, Albert J. Arias, Michaela Hoffman, Ismene Petrakis, Ralitza Gueorguieva, Joseph P. Schacht, David Oslin, Raymond F. Anton, Henry R. Kranzler

ADDICTION (2020)

Article Substance Abuse

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial

Raymond F. Anton, Konstantin E. Voronin, Sarah W. Book, Patricia K. Latham, Patrick K. Randall, Willam Bailey Glen, Michaela Hoffman, Joseph P. Schacht

ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2020)

Article Substance Abuse

Clinical and Neural Correlates of Reward and Relief Drinking

Elizabeth M. Burnette, Erica N. Grodin, Joseph P. Schacht, Lara A. Ray

Summary: The study found differences between reward and relief/habit-motivated drinking behaviors, with relief/habit drinkers exhibiting higher AUD severity on clinical measures and greater activation in the dorsal striatum in response to controlled alcohol cues. These findings contribute to a better understanding of drinking behavior categorization and treatment for AUD.

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH (2021)

Editorial Material Anesthesiology

Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders

Karsten Bartels, Joseph P. Schacht

ANESTHESIA AND ANALGESIA (2021)

Article Genetics & Heredity

Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial

Joseph P. Schacht, Michaela Hoffman, Brian H. Chen, Raymond F. Anton

Summary: The study found that methylation levels in OPRM1, SLC6A3, and COMT genes were associated with the efficacy of naltrexone in treating heavy drinking in individuals with AUD, with lower methylation levels leading to fewer heavy drinking days. This suggests that epigenetic modification of these genes could be a novel predictor of naltrexone efficacy in AUD treatment.

PHARMACOGENOMICS JOURNAL (2022)

Article Biochemical Research Methods

A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus

Hamed Ekhtiari, Mehran Zare-Bidoky, Arshiya Sangchooli, Amy C. Janes, Marc J. Kaufman, Jason A. Oliver, James J. Prisciandaro, Torsten Wustenberg, Raymond F. Anton, Patrick Bach, Alex Baldacchino, Anne Beck, James M. Bjork, Judson Brewer, Anna Rose Childress, Eric D. Claus, Kelly E. Courtney, Mohsen Ebrahimi, Francesca M. Filbey, Dara G. Ghahremani, Peyman Ghobadi Azbari, Rita Z. Goldstein, Anna E. Goudriaan, Erica N. Grodin, J. Paul Hamilton, Colleen A. Hanlon, Peyman Hassani-Abharian, Andreas Heinz, Jane E. Joseph, Falk Kiefer, Arash Khojasteh Zonoozi, Hedy Kober, Rayus Kuplicki, Qiang Li, Edythe D. London, Joseph McClernon, Hamid R. Noori, Max M. Owens, Martin Paulus, Irene Perini, Marc Potenza, Stephane Potvin, Lara Ray, Joseph P. Schacht, Dongju Seo, Rajita Sinha, Michael N. Smolka, Rainer Spanagel, Vaughn R. Steele, Elliot A. Stein, Sabine Steins-Loeber, Susan F. Tapert, Antonio Verdejo-Garcia, Sabine Vollstaedt-Klein, Reagan R. Wetherill, Stephen J. Wilson, Katie Witkiewitz, Kai Yuan, Xiaochu Zhang, Anna Zilverstand

Summary: This study established parameters and reporting standards for cue reactivity research in functional magnetic resonance imaging, and conducted a review on relevant published studies, revealing gaps in the reporting of important items.

NATURE PROTOCOLS (2022)

Article Neurosciences

Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone

Joseph P. Schacht, Yeongbin Im, Michaela Hoffman, Konstantin E. Voronin, Sarah W. Book, Raymond F. Anton

Summary: This study suggests that the COMT inhibitor tolcapone may only be effective in reducing alcohol consumption among individuals who are genetically predisposed to excessive COMT activity and potentially have low cortical dopamine levels.

NEUROPSYCHOPHARMACOLOGY (2022)

Article Neurosciences

The Neurocognitive Effects of Cannabis Across the Lifespan

Jarrod M. Ellingson, Jesse D. Hinckley, J. Megan Ross, Joseph P. Schacht, L. Cinnamon Bidwell, Angela D. Bryan, Christian J. Hopfer, Paula Riggs, Kent E. Hutchison

Summary: Research suggests that cannabis use may be associated with poorer neurocognitive functioning, especially in adolescence, but some studies have not found clear evidence of impairment. The endocannabinoid system may play a role in how cannabis affects neurocognitive functions, potentially offering protective effects in older adults.

CURRENT BEHAVIORAL NEUROSCIENCE REPORTS (2021)

Meeting Abstract Substance Abuse

PREDICTION OF ALCOHOL HARM REDUCTION OUTCOMES FROM CUE-ELICITED BRAIN ACTIVATION IN A RANDOMIZED TRIAL OF NALTREXONE

J. P. Schacht, M. Hoffman, K. E. Voronin, R. F. Anton

ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2019)

Meeting Abstract Substance Abuse

CAN DRINKING MOTIVES AND ALCOHOL WITHDRAWAL SYMPTOMS IDENTIFY SPECIFIC MEDICATION RESPONSE?

M. Hoffman, Z. Adams, J. Schacht, K. Voronin, P. Latham, E. Bristol, R. Anton

ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2019)

暂无数据